OVERVIEW
The prevalence of hepatorenal syndrome-acute kidney injury (HRS-AKI) is increasing, and HRS-AKI is associated with significantly worse patient survival and renal outcomes post- liver transplant. Following a transplant, early recognition and prompt diagnosis of HRS-AKI is vital for initiating treatment and improving outcomes, especially for the high-risk population. In this interactive MedscapeLIVE! educational symposium, a panel of experts will review guideline recommendations for managing patients with HRS-AKI, present patient cases, and ask for your guidance in making a prompt diagnosis and effectively managing these patients to improve their outcomes. Join us for this 1-hour CME-certified learning event to get the answers you need for managing your patients with HRS-AKI!
GOAL STATEMENT
The goal of this activity is for learners to be better able to recognize, diagnose, and care for patients with hepatorenal syndrome-acute kidney injury (HRS-AKI)
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have greater competence related to[LIST][ITEM]Recognizing HRS-AKI[ITEM]Selecting timely for patients with HRS-AKI[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Care for patients with HRS-AKI[/LIST]
ACCREDITATION STATEMENT
[JALOGO] [MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Manchester Grand Hyatt San Diego
Grand Ballroom A
1 Market Pl
San Diego, California, 92101-7714
United States
This symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.
Supported by an independent educational grant from [bold]Mallinckrodt Pharmaceuticals[/bold].